<DOC>
	<DOCNO>NCT02791867</DOCNO>
	<brief_summary>The primary objective determine subject take natural product AphoelineBrake™ addition standard treatment experience difference metabolic disease control , gastrointestinal hormone inflammatory marker diet , hunger , satiety , weight , compare patient take placebo addition standard treatment . The secondary objective study effect Aphoeline Brake oxidative inflammatory stress marker .</brief_summary>
	<brief_title>Comparison Laboratory Changes , Food Intake Metabolic Profile Patients With Obesity Type2 Diabetes Mellitus : Before , During After Taking AphoelineBrake</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Age ≥21 year Diagnosis T2DM Metformin first line treatment HbA1c ≥7 Calculated HOMAIR ≥3.0 , BMI 2545 Triglyceride level ≥ 2.26 mmol/L Age &lt; 21 year age BMI ≤ 25 Pregnant Subjects chronic nonsteroidal antiinflammatory drug systemic corticosteroid . Subjects treat Liraglutide ( Victoza® ) . Renal , hepatic cardiac failure . Subjects significant clinical illness within month first administration Aphoeline Brake™ Subjects diagnose Irritable Bowel Syndrome . Subjects diagnose Ulcerative Colitis Crohn 's disease . History significant gastrointestinal disease . Poor venous access . Poor likelihood adhere study procedure , document MyFitnessPal procedure prior use Aphoeline Brake™</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>